These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 15519663)

  • 1. Angiogenesis and hepatocellular carcinoma.
    Semela D; Dufour JF
    J Hepatol; 2004 Nov; 41(5):864-80. PubMed ID: 15519663
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiangiogenic strategies in hepatocellular carcinoma: current status.
    Zacharoulis D; Hatzitheofilou C; Athanasiou E; Zacharoulis S
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):645-56. PubMed ID: 16111465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma.
    Wu XZ; Xie GR; Chen D
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1178-82. PubMed ID: 17559361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting vessels to treat hepatocellular carcinoma.
    Romanque P; Piguet AC; Dufour JF
    Clin Sci (Lond); 2008 Apr; 114(7):467-77. PubMed ID: 18302534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin 8 in human hepatocellular carcinoma correlates with cancer cell invasion of vessels but not with tumor angiogenesis.
    Kubo F; Ueno S; Hiwatashi K; Sakoda M; Kawaida K; Nuruki K; Aikou T
    Ann Surg Oncol; 2005 Oct; 12(10):800-7. PubMed ID: 16132378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiogenesis and anti-angiogenesis in hepatocellular carcinoma.
    Ribatti D; Vacca A; Nico B; Sansonno D; Dammacco F
    Cancer Treat Rev; 2006 Oct; 32(6):437-44. PubMed ID: 16870349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood supply of early hepatocellular carcinoma.
    Bhattacharya S; Davidson B; Dhillon AP
    Semin Liver Dis; 1995 Nov; 15(4):390-401. PubMed ID: 8578322
    [No Abstract]   [Full Text] [Related]  

  • 8. Leptin-leptin receptor are involved in angiogenesis in human hepatocellular carcinoma.
    Ribatti D; Belloni AS; Nico B; Di Comite M; Crivellato E; Vacca A
    Peptides; 2008 Sep; 29(9):1596-602. PubMed ID: 18573568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-staging of hepatocellular carcinoma prior to liver transplantation: the power of selection.
    Ravaioli M; Grazi GL; Cescon M; Trevisani F; Piscaglia F; Ercolani G; Pinna AD
    Hepatology; 2009 Mar; 49(3):1056. PubMed ID: 19241485
    [No Abstract]   [Full Text] [Related]  

  • 10. Simulation of biphasic CT findings in hepatic cellular carcinoma by a two-level physiological model.
    Kretowski M; Bezy-Wendling J; Coupe P
    IEEE Trans Biomed Eng; 2007 Mar; 54(3):538-42. PubMed ID: 17355068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Correlation between blood flow velocity of feeding arteries and microvessel density of hepatocellular carcinoma].
    Dong L; Zhang CS; Guan YF; Zhang Y; Zhao XF
    Zhonghua Zhong Liu Za Zhi; 2005 Sep; 27(9):538-40. PubMed ID: 16438851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Changes of vascular endothelial growth factor and endothelin-1 and nitric oxide in patients with primary hepatocellular carcinoma].
    Wun T; Qian HL; Xie L; He LX; Huang DZ
    Zhonghua Gan Zang Bing Za Zhi; 2004 Jul; 12(7):441. PubMed ID: 15268819
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical significance of alpha-fetoprotein: involvement in proliferation, angiogenesis, and apoptosis of hepatocellular carcinoma.
    Mitsuhashi N; Kobayashi S; Doki T; Kimura F; Shimizu H; Yoshidome H; Ohtsuka M; Kato A; Yoshitomi H; Nozawa S; Furukawa K; Takeuchi D; Suda K; Miura S; Miyazaki M
    J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 2):e189-97. PubMed ID: 18466288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular tools and hepatocellular carcinoma: Adding help or confusion in liver transplantation?
    Vibert E; Samuel D
    J Hepatol; 2008 Oct; 49(4):498-501. PubMed ID: 18678433
    [No Abstract]   [Full Text] [Related]  

  • 15. [Expression of heparanase and b-FGF in HCC and their relationships with microvascular density].
    Wang SX; Tian ZH; Wu XH; Zhou SY; Peng L
    Zhonghua Gan Zang Bing Za Zhi; 2006 Apr; 14(4):297-8. PubMed ID: 16635305
    [No Abstract]   [Full Text] [Related]  

  • 16. Hepatocellular carcinoma: New insight into angiogenesis in hepatocellular carcinoma: involvement of microRNA-26a.
    Greenhill C
    Nat Rev Gastroenterol Hepatol; 2014 Jan; 11(1):3. PubMed ID: 24296580
    [No Abstract]   [Full Text] [Related]  

  • 17. Vascular changes in hepatocellular carcinoma.
    Yang ZF; Poon RT
    Anat Rec (Hoboken); 2008 Jun; 291(6):721-34. PubMed ID: 18484619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New strategy of antiangiogenic therapy for hepatocellular carcinoma.
    Wu XZ
    Neoplasma; 2008; 55(6):472-81. PubMed ID: 18999874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radical resection for hepatocellular carcinoma.
    Hira E; Ono T; Dhar DK; El-Assal ON; Hishikawa Y; Yamanoi A; Nagasue N
    Cancer; 2005 Feb; 103(3):588-98. PubMed ID: 15612021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mTOR inhibitors for hepatocellular cancer: a forward-moving target.
    Treiber G
    Expert Rev Anticancer Ther; 2009 Feb; 9(2):247-61. PubMed ID: 19192962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.